Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)

December 20, 2022

https://www.globenewswire.com/news-release/2022/12/20/2576945/0/en/Altimmune-Announces-Positive-Topline-Results-from-24-Week-12-Week-Extension-Trial-of-Pemvidutide-in-Subjects-with-Non-Alcoholic-Fatty-Liver-Disease-NAFLD.html

GAITHERSBURG, Md., Dec. 20, 2022 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq:ALT), a clinical-stage biopharmaceutical company, today announced topline results from its 24-week (12-week extension) trial of pemvidutide in subjects with NAFLD.

Read more at globenewswire.com

Related news for (ALT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.